Skip to content
    Compare notes on r/BodyHackGuideCompare notes with other researchers. Join r/BodyHackGuide

    TB-500

    Injury, Repair & Recovery

    Status
    Preclinical, , not approved for human use
    Evidence

    No human trials of the fragment, graded on 2 research benches

    TB-500 is the name the market and the FDA use for a short synthetic fragment of thymosin beta-4: the seven-amino-acid, N-acetylated actin-binding sequence Ac-LKKTETQ (residues 17 to 23).

    Reviewed

    01Overview

    What TB-500 is

    Thymosin beta-4 itself is a 43-amino-acid peptide (about 4963 Da acetylated) and one of the most abundant intracellular actin-sequestering molecules in mammalian cells. The two are not the same molecule. Analytical work on internet-sold TB-500 found products that did not match their descriptions (PMID: 36482504), and a 2024 metabolite study states that the biological effects of the acetylated TB-500 fragment have not been documented (PMID: 38382158). The sequence and mass on a lot certificate of analysis are the only way to know which form a vial holds.

    Read the full overviewShow less

    The foundational review by Goldstein et al. (2005) established full-length thymosin beta-4 as a multifunctional regenerative peptide with roles spanning wound healing, angiogenesis, anti-inflammation, and cardiac repair. Unlike many bioactive peptides, thymosin beta-4 is not a hormone or cytokine but rather an intracellular actin-regulatory protein that, when released extracellularly following injury, initiates paracrine signaling cascades that drive tissue repair. Most of what follows is full-length thymosin beta-4 data; the fragment's efficacy data appears only in the wound-healing paragraph.

    Thymosin beta-4 has been studied extensively in preclinical models of cardiac injury. Bock-Marquette et al. (2004) demonstrated that thymosin beta-4 promotes survival of cardiomyocytes after experimental myocardial infarction in mice, reduces infarct size, and improves cardiac function. The mechanism involves activation of the Akt (protein kinase B) survival pathway and migration of cardiomyocytes and endothelial cells toward the injury. These findings positioned thymosin beta-4 as a candidate cardiac repair agent, though clinical translation has been limited.

    In wound healing research, thymosin beta-4 accelerates dermal wound closure by promoting keratinocyte and endothelial cell migration, increasing angiogenesis, and reducing inflammation at the wound site. Philp et al. (2003) showed that topical thymosin beta-4 significantly accelerated full-thickness wound closure in diabetic and aged mouse models, and in the same paper the free seven-residue fragment LKKTETQ promoted repair in aged animals comparable to the parent peptide (PMID: 12581423). That one mouse study, plus in-vitro assays, is the fragment record; there is no human data for the fragment.

    Thymosin beta-4 has also shown efficacy in corneal wound healing models. Sosne et al. demonstrated that thymosin beta-4 eye drops accelerate corneal epithelial wound closure and reduce inflammation after chemical or mechanical injury, leading to ophthalmic clinical trials (Phase 2 and Phase 3, RGN-259) for dry eye and neurotrophic keratopathy. This is the most advanced clinical development program for any thymosin beta-4-based therapeutic, and it is topical.

    TB-500 is not FDA-approved for any human therapeutic indication. It is a doping-control target in racing horses (PMID: 23084823) and is used in the human peptide biohacking community for musculoskeletal recovery, wound healing, and anti-inflammatory effects, on the strength of the full-length peptide literature rather than any human fragment data. On 28 October 2026 HHS announced a draft interim policy covering TB-500 acetate for subcutaneous or intramuscular use. Under it, HHS does not intend to take enforcement action against state-licensed pharmacies, federal facilities or licensed physicians that compound it under set conditions, including a single active ingredient per product. The policy is not an approval, and an FDA advisory committee's July 2026 vote to recommend adding TB-500 to the 503A bulks list of substances pharmacies may compound from is not binding.

    How it works

    Actin Sequestration and Cytoskeletal Dynamics

    The primary molecular function of thymosin beta-4 (and the synthetic peptide sold as TB-500) is binding to monomeric G-actin in a 1:1 complex, preventing its polymerization into F-actin filaments (PMID: 1627561). By maintaining a pool of sequestered G-actin, thymosin beta-4 enables rapid cytoskeletal reorganization when cells need to migrate, divide, or change shape. This actin-sequestering function is critical during wound healing because it allows keratinocytes, endothelial cells, and fibroblasts to rapidly mobilize to injury sites. The actin-binding activity centers on the conserved LKKTETQ motif (residues 17-23, a 7-amino-acid sequence), an example of the beta-thymosin/WH2 actin-binding fold (PMID: 17468236); this heptapeptide lies within the full-length thymosin beta-4 molecule that TB-500 reproduces.

    Read the full mechanismShow less

    Angiogenesis Promotion

    TB-500 promotes the formation of new blood vessels through multiple mechanisms. Thymosin beta-4 stimulates endothelial cell migration and tube formation in Matrigel assays, upregulates VEGF expression, and promotes vascular sprouting in ischemic tissues. In cardiac injury models, thymosin beta-4 treatment increased capillary density in the peri-infarct region, improving oxygen delivery to surviving cardiomyocytes and reducing subsequent fibrosis. The pro-angiogenic effect is mediated partly through activation of the integrin-linked kinase (ILK) and Akt survival pathways.

    Anti-Inflammatory Signaling

    Thymosin beta-4 suppresses inflammatory signaling through downregulation of NF-kB nuclear translocation and reduction of pro-inflammatory cytokine production (TNF-alpha, IL-1beta, IL-6). In wound healing models, TB-500-treated animals showed reduced neutrophil infiltration and earlier transition from the inflammatory phase to the proliferative phase of repair. This anti-inflammatory property is complementary to its pro-migratory effects, creating a tissue environment that favors regeneration over fibrotic scar formation.

    Cardiac Repair and Progenitor Cell Activation

    In the context of myocardial infarction, thymosin beta-4 activates epicardium-derived progenitor cells (EPDCs), stimulating them to differentiate into endothelial cells and smooth muscle cells that contribute to vascular regeneration. This mechanism involves upregulation of the transcription factor Wilms tumor 1 (WT1) and activation of the Akt/mTOR survival pathway in cardiomyocytes. In preclinical models, thymosin beta-4 reduces apoptosis of cardiomyocytes under ischemic stress by promoting Akt phosphorylation, which inhibits the pro-apoptotic protein Bad (PMID: 17600280).

    Studied for

    • Cardiac repair
    • Wound healing
    • Dry eye syndrome
    • Corneal healing
    • Muscle injury

    Benefits listed

    • Accelerated dermal wound healing through enhanced keratinocyte and fibroblast migration, collagen deposition, and angiogenesis, including in diabetic and aged models (PMID: 12581423)
    • Cardioprotection and tissue repair after myocardial infarction via ILK/Akt survival signaling in preclinical models (PMID: 17600280)
    • Anti-inflammatory effects via NF-kB suppression and reduced pro-inflammatory cytokines (preclinical)
    • Corneal wound healing and dry eye symptom improvement in topical ophthalmic (RGN-259) Phase 2 trials (PMID: 25826322)
    Show 3 moreShow less
    • Enhanced hair follicle stem cell migration associated with hair growth (preclinical)
    • Musculoskeletal recovery through collagen deposition and matrix remodeling (preclinical)
    • Endothelial cell migration and vascular regeneration in ischemic tissues (preclinical)

    02Research

    Free with email

    What the research shows

    Graded on 2 research benches

    Reference pages that put TB-500 next to the compounds people pair it with: roles, evidence, overlap and conflicts. No dosing. Research use only.

    Unlock the research summary

    Enter your email to keep reading. It is free, and it opens these sections on every compound page in this browser.

    • A summary of the key research
    • Safety and side effects
    • A link to the PubMed results

    You also get the free peptide cheat sheet by email. Unsubscribe anytime.

    Have an account? Sign in

    03Safety

    TB-500 side effects and interactions

    Side effects

    Common

    • Injection site discomfort (subcutaneous administration)
    • Mild fatigue or lethargy in the days following initial doses
    • Temporary head rush or flushing reported anecdotally

    Serious events

    • No serious adverse events in published preclinical literature
    • Theoretical risk of promoting growth of existing tumors due to angiogenic properties
    • Limited human safety data — most evidence from animal models and equine use

    Who should not use it

    Contraindications

    Active cancer (theoretical concern with tissue growth promotion). Pregnancy or breastfeeding. Known hypersensitivity to thymosin beta-4 fragments.

    Interactions

    5 pairings in our record: 3 with a caution and 2 noted as compatible or synergistic. Compatible and synergistic are notes from the record, not safety findings.

    • BPC-157

      Caution

      Commonly paired, but the one controlled study of the pair, in rats with repaired Achilles tendons, found no added benefit over either peptide alone (PMID: 42542926). FDA's adverse event database also holds a report of skin and gum darkening, recurring on rechallenge, with a research product containing both.

    • GHK-Cu

      Caution

      No study has tested TB-500 and GHK-Cu together, so any added benefit is unmeasured.

    • IGF-1 LR3

      Caution

      Both promote cell proliferation — monitor for excessive tissue growth

    • Thymosin Alpha-1

      Compatible

      TA1 boosts immune function while TB-500 handles tissue repair — non-overlapping

    • MK-677

      Compatible

      GH support from MK-677 complements TB-500 tissue repair mechanisms

    This interaction data is compiled from published research and community reports. It may not be exhaustive. Always consult a healthcare professional before combining compounds.

    Need bloodwork before starting?

    Full hormone + metabolic panels from Anabolic Insights. Code CHONCH for first-order discount.

    Order Bloodwork

    04Dosing

    Free with email

    TB-500 dosage and protocols

    Dose range
    2000-5000 mcg (2-5 mg) subcutaneous 2x weekly loading; 2000 mcg (2 mg) weekly maintenance
    Dosing
    2x per week during loading; 1x per week maintenance
    Common vials
    2mg, 5mg, 10mg

    Unlock the dosing protocols

    Enter your email to keep reading. It is free, and it opens these sections on every compound page in this browser.

    • Dose, route, how often and how long
    • A titration schedule
    • Beginner, intermediate and advanced protocols
    • Reconstitution and handling notes

    You also get the free peptide cheat sheet by email. Unsubscribe anytime.

    Have an account? Sign in

    05Prices

    TB-500 prices

    8 listings from 4 vendors, opening in the Featured order.

    Pack prices
    $29.00 to $64.99
    Lowest per mg
    $4.90/mg
    Vendors
    4
    Listings
    8 (vial)

    Prices as the vendors list them, last recorded 8 October 2026.

    Size
    Form
    Sort
    TB-500 listings, in Featured order
    VendorProductPriceBuy

    TB-500 (vial)

    vial, 1 vial

    In stock

    $64.99

    No mg count

    Buy TB-500 (vial) at Disguised Alpha

    TB-500 5mg

    vial, 1 vial

    In stock

    $5.80/mg

    $29.00

    Buy TB-500 5mg at Ion Peptide

    TB-500 10mg

    vial, 1 vial

    In stock

    $4.90/mg

    $49.00

    Lowest per mg
    Buy TB-500 10mg at Ion Peptide

    TB-500 20mg

    vial, 1 vial

    Out of stock

    $4.45/mg

    $89.00

    View TB-500 20mg at Ion Peptide

    TB-500 5mg

    vial, 1 vial

    In stock

    $7.00/mg

    $34.99

    Buy TB-500 5mg at BioMyst Labs

    TB-500 5mg

    vial, 1 vial

    In stock

    $7.40/mg

    $36.99

    Buy TB-500 5mg at BioMyst Labs

    TB-500 5mg

    vial, 5mg vial

    In stock

    $7.00/mg

    $34.99

    Buy TB-500 5mg at Half Nattys

    TB-500 10mg

    vial, 10mg vial

    In stock

    $5.00/mg

    $49.99

    Buy TB-500 10mg at Half Nattys
    Vendors selling TB-500(4: trust score, certificates, payment, shipping)

    Every supplier above is graded 0 to 100 on COA verification, payment transparency, shipping, reviews, and active listings. Methodology published, no pay-to-rank. How we score these vendors

    Price history(4 days with a recorded price)
    Review TB-500

    Sign in to leave a review

    Reviews on BodyHackGuide are tied to verified user accounts and moderated before publishing. Sign in (free, no spam) to share your experience with TB-500.

    06Chemistry

    Chemistry and structure

    Molecular formula
    C38H68N10O14 (Ac-LKKTETQ); full-length thymosin beta-4 is C212H350N56O78S
    Molecular mass
    889.0 g/mol (Ac-LKKTETQ); 846.97 g/mol (LKKTETQ, free); full-length thymosin beta-4 4963.4 g/mol acetylated
    CAS number
    885340-08-9
    IUPAC name
    N-acetyl-L-leucyl-L-lysyl-L-lysyl-L-threonyl-L-alpha-glutamyl-L-threonyl-L-glutamine
    Amino acid sequence
    Ac-LKKTETQ (thymosin beta-4 residues 17-23). Full-length thymosin beta-4 for comparison: Ac-SDKPDMAEIEKFDKSKLKKTETQEKNPLPSKETIEQEKQAGES
    Half-life
    Plasma half-life is short - full-length thymosin beta-4 clears on the order of hours, while the short LKKTETQ actin-binding fragment clears within minutes. Tissue-level regenerative effects persist substantially longer than plasma exposure.
    View on PubChem

    08Questions

    Frequently asked questions

    What is TB-500 used for in research?

    TB-500 is the name the market and the FDA use for a short synthetic fragment of thymosin beta-4: the seven-amino-acid, N-acetylated actin-binding sequence Ac-LKKTETQ (residues 17 to 23). Thymosin beta-4 itself is a 43-amino-acid peptide (about 4963 Da acetylated) and one of the most abundant intracellular actin-sequestering molecules in mammalian cells. The two are not the same molecule. Analytical work on internet-sold TB-500 found products that did not match their descriptions (PMID: 36482504), and a 2024 metabolite study states that the biological effects of the acetylated TB-500 fragment have not been documented (PMID: 38382158). The sequence and mass on a lot certificate of analysis are the only way to know which form a vial holds.

    The foundational review by Goldstein et al. (2005) established full-length thymosin beta-4 as a multifunctional regenerative peptide with roles spanning wound healing, angiogenesis, anti-inflammation, and cardiac repair. Unlike many bioactive peptides, thymosin beta-4 is not a hormone or cytokine but rather an intracellular actin-regulatory protein that, when released extracellularly following injury, initiates paracrine signaling cascades that drive tissue repair. Most of what follows is full-length thymosin beta-4 data; the fragment's efficacy data appears only in the wound-healing paragraph.

    Thymosin beta-4 has been studied extensively in preclinical models of cardiac injury. Bock-Marquette et al. (2004) demonstrated that thymosin beta-4 promotes survival of cardiomyocytes after experimental myocardial infarction in mice, reduces infarct size, and improves cardiac function. The mechanism involves activation of the Akt (protein kinase B) survival pathway and migration of cardiomyocytes and endothelial cells toward the injury. These findings positioned thymosin beta-4 as a candidate cardiac repair agent, though clinical translation has been limited.

    In wound healing research, thymosin beta-4 accelerates dermal wound closure by promoting keratinocyte and endothelial cell migration, increasing angiogenesis, and reducing inflammation at the wound site. Philp et al. (2003) showed that topical thymosin beta-4 significantly accelerated full-thickness wound closure in diabetic and aged mouse models, and in the same paper the free seven-residue fragment LKKTETQ promoted repair in aged animals comparable to the parent peptide (PMID: 12581423). That one mouse study, plus in-vitro assays, is the fragment record; there is no human data for the fragment.

    Thymosin beta-4 has also shown efficacy in corneal wound healing models. Sosne et al. demonstrated that thymosin beta-4 eye drops accelerate corneal epithelial wound closure and reduce inflammation after chemical or mechanical injury, leading to ophthalmic clinical trials (Phase 2 and Phase 3, RGN-259) for dry eye and neurotrophic keratopathy. This is the most advanced clinical development program for any thymosin beta-4-based therapeutic, and it is topical.

    TB-500 is not FDA-approved for any human therapeutic indication. It is a doping-control target in racing horses (PMID: 23084823) and is used in the human peptide biohacking community for musculoskeletal recovery, wound healing, and anti-inflammatory effects, on the strength of the full-length peptide literature rather than any human fragment data. On 28 October 2026 HHS announced a draft interim policy covering TB-500 acetate for subcutaneous or intramuscular use. Under it, HHS does not intend to take enforcement action against state-licensed pharmacies, federal facilities or licensed physicians that compound it under set conditions, including a single active ingredient per product. The policy is not an approval, and an FDA advisory committee's July 2026 vote to recommend adding TB-500 to the 503A bulks list of substances pharmacies may compound from is not binding.

    What forms does TB-500 come in?

    TB-500 is available in vial form.

    How do I compare TB-500 vendors?

    Compare prices, payment methods, shipping, and COA scores across 4 vendors.

    How many vendors sell TB-500, and what does it cost per mg?

    4 of the vendors BodyHackGuide tracks list TB-500 (8 listings). Among BodyHackGuide's TB-500 listings recorded as in stock with a milligram count, the lowest price per milligram is $4.90/mg at Ion Peptide and the median is $6.40/mg. The TB-500 prices on BodyHackGuide are vendors' listed prices as BodyHackGuide last recorded them, not transactions; the most recent recorded change to a TB-500 listing is dated 8 October 2026.

    Which vendors have third-party COAs for TB-500 on file at BodyHackGuide?

    BodyHackGuide holds 125 third-party certificate records for TB-500, from ResearchChemHQ and Half Nattys. An editor has read 1 of BodyHackGuide's 125 certificate records for TB-500 and recorded the laboratory, the compound and the test date as printed on each. The laboratories named on BodyHackGuide's TB-500 certificate records are Janoshik Analytical and Freedom Diagnostics Testing, and the newest test date on them is 6 October 2026. Each vendor page on BodyHackGuide shows how many certificate records BodyHackGuide holds for that vendor and links to each record that has its own page.

    Related

    Articles on TB-500

    Free 2026 Peptide Cheat Sheet (PDF)

    38 compounds and blends: vial sizes, BAC water volumes, dosing ranges and bloodwork markers.

    Download Free